Quick Answer
Pharma-Bio Serv, Inc. reported Total Revenue of $9.00 million for fiscal year 2025.
Pharma-Bio Serv, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $9.00M -5.3% |
$9.51M -44.0% |
$16.98M -12.5% |
$19.40M -3.6% |
$20.12M -6.7% |
$21.56M +10.5% |
| Net Income | -$100.5K +87.1% |
-$777.6K -159.4% |
$1.31M +30.1% |
$1.01M +148.2% |
-$2.09M -201.9% |
$2.05M -1.7% |
| Diluted EPS | -$0.00 +88.2% |
-$0.03 -159.6% |
$0.06 | — | — | — |
| Total Assets | $13.65M -16.2% |
$16.29M -18.1% |
$19.90M -3.6% |
$20.65M -13.7% |
$23.92M -20.0% |
$29.92M +12.3% |
| Cash and Equivalents | — | — | — | $14.46M -17.2% |
$17.47M +1.9% |
$17.14M +10.6% |
| Stockholders Equity | $11.91M -13.1% |
$13.72M -15.0% |
$16.13M -2.6% |
$16.56M -12.5% |
$18.91M -16.7% |
$22.72M +10.2% |
| Operating Income | -$637.7K +50.5% |
-$1.29M -215.2% |
$1.12M -4.9% |
$1.17M +130.5% |
-$3.85M -273.2% |
$2.23M +31.2% |
| Gross Profit | $2.91M +15.7% |
$2.52M -50.3% |
$5.07M +3.8% |
$4.88M -8.9% |
$5.36M -19.6% |
$6.67M +7.9% |
| Shares Outstanding | 22.91M -0.2% |
22.96M -0.0% |
22.96M +0.1% |
22.94M -0.3% |
23.00M +0.0% |
23.00M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | January 31, 2026 | $2.29M | -7.1% | +16.9% |
| Net Income | January 31, 2026 | $32.9K | +285.0% | +116.1% |
| Diluted EPS | January 31, 2026 | $0.00 | — | -88.9% |
| Total Assets | January 31, 2026 | $13.55M | -15.7% | -0.8% |
| Cash and Equivalents | July 31, 2023 | $2.87M | -79.8% | -64.6% |
| Stockholders Equity | January 31, 2026 | $10.24M | -14.6% | -14.1% |
| Operating Income | January 31, 2026 | -$94.5K | -2.5% | +69.9% |
| Gross Profit | January 31, 2026 | $722.4K | -6.0% | +25.8% |
| Shares Outstanding | January 31, 2026 | 22.90M | -0.2% | -0.0% |
- Pharma-Bio Serv, Inc. reported Total Revenue of $9.00 million for fiscal year 2025.
- Pharma-Bio Serv, Inc. showed a decrease of -5.3% in Total Revenue compared to the prior fiscal year.
- Pharma-Bio Serv, Inc. reported Net Income of -$100.5 thousand for fiscal year 2025.
- Pharma-Bio Serv, Inc. showed an increase of +87.1% in Net Income compared to the prior fiscal year.
- Pharma-Bio Serv, Inc. reported Diluted EPS of $0.00 per share (loss) for fiscal year 2025.
- Pharma-Bio Serv, Inc. showed an increase of +88.2% in Diluted EPS compared to the prior fiscal year.
- Pharma-Bio Serv, Inc. reported Total Assets of $13.65 million for fiscal year 2025.
- Pharma-Bio Serv, Inc. showed a decrease of -16.2% in Total Assets compared to the prior fiscal year.
- Pharma-Bio Serv, Inc. reported Cash and Equivalents of $14.46 million for fiscal year 2022.
- Pharma-Bio Serv, Inc. showed a decrease of -17.2% in Cash and Equivalents compared to the prior fiscal year.
- Pharma-Bio Serv, Inc. reported Stockholders Equity of $11.91 million for fiscal year 2025.
- Pharma-Bio Serv, Inc. showed a decrease of -13.1% in Stockholders Equity compared to the prior fiscal year.
- Pharma-Bio Serv, Inc. reported Operating Income of -$637.7 thousand for fiscal year 2025.
- Pharma-Bio Serv, Inc. showed an increase of +50.5% in Operating Income compared to the prior fiscal year.
- Pharma-Bio Serv, Inc. reported Gross Profit of $2.91 million for fiscal year 2025.
- Pharma-Bio Serv, Inc. showed an increase of +15.7% in Gross Profit compared to the prior fiscal year.
- Pharma-Bio Serv, Inc. reported Shares Outstanding of 22.91 million shares for fiscal year 2025.
- Pharma-Bio Serv, Inc. showed a decrease of -0.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: